Tenofovir disoproxil
- Generic Name
- Tenofovir disoproxil
- Brand Names
- Atripla, Cimduo, Complera, Delstrigo, Stribild, Symfi, Truvada, Viread, Tenofovir disoproxil Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C19H30N5O10P
- CAS Number
- 201341-05-1
- Unique Ingredient Identifier
- F4YU4LON7I
- Background
Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). This drug is prescribed in combination with other drugs for the management of HIV infection as well as for Hepatitis B therapy. Tenofovir disoproxil was initially approved in 2001 .
- Indication
Tenofovir disoproxil is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients ≥2 years old and weighing ≥10 kg. It is also indicated for the treatment of chronic hepatitis B in patients ≥2 years old and weighing ≥10 kg.
Tenofovir disoproxil is also an ingredient in several combination products, all of which are indicated either alone or in combination with other antiretrovirals for the treatment of HIV-1 infection.
In addition, tenofovir disoproxil is available in combination with emtricitabine (under the brand name Truvada) for use as pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents weighing ≥ 35kg to reduce the risk of sexually-acquired HIV-1 infection.
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil
- Conditions
- HIVDrugResistance
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 2500
- Registration Number
- NCT04453436
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT04439539
- Locations
- 🇬🇧
Kings College Hospital, London, United Kingdom
🇬🇧Grahame Hayton Unit, London, United Kingdom
🇺🇸Ruane Clinical Research Group Inc, Los Angeles, California, United States
Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients
- Conditions
- HIV-infection/Aids
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- HeNan Sincere Biotech Co., Ltd
- Target Recruit Count
- 720
- Registration Number
- NCT04303598
- Locations
- 🇨🇳
Beijing DiTan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China
🇨🇳Chongqing Public Health Medical Center, Chongqing, Chongqing, China
Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis
- Conditions
- Hepatitis BCompensated Cirrhosis
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 150
- Registration Number
- NCT04196998
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b
- Conditions
- Chronic Hepatitis b
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 300
- Registration Number
- NCT04195074
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
- Conditions
- Hepatocellular CarcinomaCompensated CirrhosisHepatitis B, Chronic
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Qing XIe
- Target Recruit Count
- 4000
- Registration Number
- NCT04160897
- Locations
- 🇨🇳
Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 440
- Registration Number
- NCT04135235
- Locations
- 🇨🇳
Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China
Tenofovir in Pregnancy to Prevent Mother to Child Transmission of Hepatitis B.
- Conditions
- Hepatitis BTenofovirPregnancy
- Interventions
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 27
- Registration Number
- NCT04114890
- Locations
- 🇹🇭
Shoklo Malaria Research unit (SMRU) clinics, Mae sot, Tak, Thailand
A Study of Baricitinib in Participants With Rheumatoid Arthritis
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1300
- Registration Number
- NCT04086745
- Locations
- 🇺🇸
Arizona Research Clinic PLLC, Chandler, Arizona, United States
🇺🇸Smart Cures Clinical Research, Anaheim, California, United States
🇺🇸Wallace Rheumatic Study Center, Beverly Hills, California, United States
RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection
- Conditions
- HBV CoinfectionHCC
- Interventions
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT04032860
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.